Virax Biolabs
VRAX
4 hedge funds and large institutions have $22.8K invested in Virax Biolabs in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, 1 reducing their positions, and 4 closing their positions.
0.05% less ownership
Funds ownership: 0.05% → 0% (-0.05%)
20% less funds holding
Funds holding: 5 → 4 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
98% less capital invested
Capital invested by funds: $1.14M → $22.8K (-$1.12M)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$10.8K |
| 2 |
Millennium Management
New York
|
+$5.5K |
| 3 |
Wells Fargo
San Francisco,
California
|
+$880 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$1.04M |
| 2 |
Legal & General Group
London,
United Kingdom
|
-$68.4K |
| 3 |
HF
HRT Financial
New York
|
-$10K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$2.86K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$2.13K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $10K | +$10.8K | +98 | New |
|
|
TSS
2
Two Sigma Securities
New York
| $7.08K | -$2.86K | -26 | -26% |
|
|
3
Millennium Management
New York
| $4.9K | +$5.5K | +50 | New |
|
|
4
Wells Fargo
San Francisco,
California
| $780 | +$880 | +8 | New |
|
|
AC
5
Armistice Capital
New York
| – | -$1.04M | -6,000 | Closed |
|
|
6
Legal & General Group
London,
United Kingdom
| – | -$68.4K | -399 | Closed |
|
|
HF
7
HRT Financial
New York
| – | -$10K | -62 | Closed |
|
|
8
UBS Group
Zurich,
Switzerland
| – | -$2.13K | -12 | Closed |
|
VRAX Hedge Fund Activity: Q2 2023 in Review
4 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Virax Biolabs (VRAX) for Q2 2023, worth a combined $22.8K — down 98% from $1.14M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of VRAX and 3 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 0 added.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $10.8K. The largest seller was Armistice Capital, exiting entirely with an estimated $1.04M sold.
- 4 institutional investors held Virax Biolabs (VRAX) as of Q2 2023, down from 5 in Q1 2023.
- Funds reported $22.8K of Virax Biolabs stock for Q2 2023, down 98% quarter-over-quarter.
- 3 funds opened new Virax Biolabs positions in Q2 2023 and 4 closed out, a net change of -1 holder.
- The largest Virax Biolabs buyer in Q2 2023 was Renaissance Technologies, an estimated $10.8K added.
- The largest Virax Biolabs seller in Q2 2023 was Armistice Capital, an estimated $1.04M sold.
Based on aggregated 13F filings for Q2 2023.